Valtech Cardio, Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Valtech Cardio, Ltd.
Market Brief: Innovation Will Drive 13% Growth In Global Transcatheter Mitral Valve Repair Market by 2023, Outpacing Growth Of TAVR
The transcatheter heart valve management products market will reach $6.7bn by 2023, driven by the rising prevalence of heart disease. Transcatheter aortic valve replacement (TAVR) procedures lead the market, but innovation and rising competition, including from companies in China and India, will fuel double-digit growth in the much smaller mitral valve repair market, dominated by Abbott's MitraClip.
Harpoon is a minimally invasive surgery device that complements Edwards pipeline of transcatheter mitral and septal valve repair and replacement technologies, which now includes at least six technologies at various stages of development, and is one of the company's top R&D priorities.
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial announcements, initiations, completions, and suspensions each month. This month's edition, covering the period between mid-July and mid-August, includes trials from the biggest medtech players, some start-ups, and companies of every size in between.
The TRILUMINATE trial will evaluate safety and effectiveness of its Tricuspid Valve Repair System for treating symptomatic moderate-to-severe tricuspid regurgitation. The device is similar to Abbott's successful MitraClip catheter-based device for treating mitral regurgitation.